PHARMA
3SBio & Selecta To Develop Non-Immunogenic Gout Drug
By combining pegsiticase with Selecta's synthetic vaccine particle platform, 3SBio hopes to develop an anti-gout drug that will not be affected by drug resistance.
Eisai Completes Phase III Trial For Epilepsy Drug
The Phase III clinical trial for Eisai's in-house developed AMPA receptor antagonist Fycompa® has met its primary endpoints in patients with severe seizures.
Hilleman & Gotovax Collaborate On Cholera Vaccine
The oral cholera vaccine currently in preclinical development will be cheaper, easy to administer and cross-protective for different types of bacteria.
China’s CBMG Begins Trading On NASDAQ
Cellular Biomedicine Group, which develops cell therapeutics targeted at the Chinese market, has listed on NASDAQ.
Artemether, Guilin Pharma’s First WHO-certified API
Guilin Pharma has received its first WHO product quality certification for the anti-malaria drug Artemether, paving the way for other drugs in its portfolio.
MacroGenics & Takeda Develop Bi-Specific Antibodies For Autoimmune Diseases
MGD010, which simultaneously targets the cell surface receptors CD32B and CD78B, could help modulate B cell function without causing depletion.
Eisai & KRI Open New Research Facility In Kobe
The new facility located in the Kansai International Strategic Innovation Zone will focus on developing biologic therapies.
Astellas’ Prostate Cancer Drug Available In Japan
The androgen receptor signaling inhibitor XTANDI® has been approved for castration-resistant prostate cancer in Japan.
Agenix Sells HBV Drug To Cinkate For USD$2 Million
With the sale of its patented hepatitis drug AGX-1009 to Cintake, Agenix has exited all operations in China.
